Protocol Ledger

NCT05173987 · Phase III · ACTIVE NOT RECRUITING

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Interventional Phase III clinical trial protocol NCT05173987 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-03 Enrollment: 280 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05173987
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)280 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05173987
Protocol FieldVerified Registry Value
NCT IdentifierNCT05173987
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment280 participants (ESTIMATED)
Registered Start Date2022-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI